Mabpharm Limited (HK:2181) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Mabpharm Limited has received approval from the Indonesian National Agency of Drug and Food Control for their core product, CMAB008 (infliximab for injection), to treat several conditions including ulcerative colitis and rheumatoid arthritis. This biosimilar medicine, originating from China, offers a more economical option for patients due to its inclusion in China’s basic medical insurance program. Investors may find this approval promising as it expands Mabpharm’s market reach and potential revenue streams.
For further insights into HK:2181 stock, check out TipRanks’ Stock Analysis page.